Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials

Panitumumab is approved for RAS wild‐type metastatic colorectal cancer and was evaluated in Phase III (PRIME, NCT00364013) and Phase II (PEAK, NCT00819780) first‐line randomised studies. This retrospective analysis of these trials investigated efficacy and toxicity of panitumumab‐based maintenance a...

Descripción completa

Detalles Bibliográficos
Autores principales: Modest, Dominik Paul, Rivera, Fernando, Bachet, Jean‐Baptiste, de Braud, Filippo, Pietrantonio, Filippo, Koukakis, Reija, Demonty, Gaston, Douillard, Jean‐Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590196/
https://www.ncbi.nlm.nih.gov/pubmed/30614531
http://dx.doi.org/10.1002/ijc.32110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590196/
https://www.ncbi.nlm.nih.gov/pubmed/30614531
http://dx.doi.org/10.1002/ijc.32110

Ejemplares similares